Pretransplant assessment of the risk for posttransplant lymphoproliferative disorder

Transplant Proc. 1995 Oct;27(5 Suppl 1):41.
No abstract available

MeSH terms

  • Antilymphocyte Serum / therapeutic use
  • Confidence Intervals
  • Cytomegalovirus Infections / complications
  • Graft Rejection / immunology
  • Graft Rejection / therapy
  • Herpesvirus 4, Human / isolation & purification
  • Humans
  • Incidence
  • Lymphoproliferative Disorders / epidemiology*
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / prevention & control
  • Muromonab-CD3 / adverse effects
  • Muromonab-CD3 / therapeutic use
  • Postoperative Complications / epidemiology*
  • Postoperative Complications / prevention & control
  • Retrospective Studies
  • Risk Factors
  • Transplantation*

Substances

  • Antilymphocyte Serum
  • Muromonab-CD3